View clinical trials related to Mononeuropathies.
Filter by:Common peroneal mononeuropathy at the fibular neck (CPN) is one of the most frequent mononeuropathies of the lower extremities. The common peroneal nerve sub serves sensation to the dorsum of the foot and toes. In CPN motor fibers of the deep peroneal nerve are more frequently affected than those of the superficial peroneal nerve. Fascicles of the deep branch of the common peroneal nerve are more anteriorly located and more vulnerable to injury than those of the superficial peroneal branch. The clinical and electrodiagnostic findings in CPN resemble the anatomical structure of the common peroneal nerve, indeed fibers for the deep peroneal nerve and the superficial peroneal nerve are bounded in separate fascicles along the course of the nerve. Superficial peroneal nerve sensory potential (SPSP) should be performed to localize the site of injury. Electrodiagnostic testing is used widely to evaluate the function of the common peroneal nerve. SPSP have been examined in CPN with conflicting results. A loss in amplitude of this response implies some axonal loss affecting either the common peroneal nerve or its superficial branch. Prominent axonal loss is the hallmark of most CPN lesions and suggested that abnormalities in sensory nerves mirror those in motor nerves. Moreover, assessment of the structure of the common peroneal nerve is likely to improve the diagnostic yield" by using high-resolution ultrasonography. Ultrasound imaging is painless, does not expose the patient to radiation, and has several advantages compared with magnetic resonance imaging in the laboratory setting, including reduced cost, accessibility, ability to image the entire length of the nerve in a single study, and the ability to image both statically and dynamically. This study was conducted to evaluate the superficial peroneal sensory potential and high-resolution ultrasonography role in confirmation of common peroneal mononeuropathy at the fibular neck.
A multi-center, randomized, double-blind, parallel, active-controlled phase III clinical trial to evaluate the efficacy and safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in peripheral neuropathic pain
This study is utilizing ultrasound measurement to measure neuromuscular disease status in adult patients. The hypothesis is the by quantifying ultrasound data, it is possible that ultrasound can be utilized as a tool to determine if a disease is responding to therapy or progressing.
1. Objectives: 1. To assess the efficacy of Photon Stimulation compared with placebo, in treating the pain of diabetic neuropathy. 2. To show that Photonic Stimulation for the treatment of painful diabetic neuropathy is cost effective compared to traditional medical interventions. The latter will be explored by an extensive search of the literature and from an equal number of patients being treated in traditional medical practices using traditional medical interventions. At the conclusion of the study the data will be analyzed for cost-benefits and the possibility of crafting a best-practices approach to treat these syndromes that cost billions of dollars a year in health care expenses and lost productivity. 2. Research Design This is a double blinded, randomized, placebo-controlled study of 120 patients with painful diabetic neuropathy. These 120 will be randomly assigned treatments utilizing Photon Therapy, using a defined treatment protocol. We expect that some patients will drop out, and our goal is 100 treated patients, for statistical purposes. The Photon Therapy group will be split into two groups, one group that receives Active Photon Therapy and one group that will be treated with the same type of equipment that has been modified to emit no infrared photons (Non Active Photon Therapy Group ("Placebo")). The patients in the "Non Active Photon Therapy Group" will be offered an Active Photon Treatment Session after completion of the study. The patients in the Photon Therapy Groups will be randomized. There will also be an Historical Control Group of patients, fifty, will have received traditional medical interventions (e.g., narcotics, seizure medications) in traditional medical practices. Data from these individuals will be used to calculate potential cost savings. 3. Methodology: Subjects who meet the inclusion and exclusion criteria and have signed a valid informed consent will be eligible to participate in the study. After screening, subjects in the Photon Therapy groups (both active and nonactive) will undergo four treatment sessions. The first treatment session will vary from the second, third and fourth. During all treatment session, each patient will be imaged with the TIP Infrared Camera before, and after treatment. Infrared imaging can visualize skin temperature changes in a noninvasive manner (2). The first treatment will utilize slightly different protocol than subsequent visits, reduced Photon dosage, 120 instead of 240 joules. Proprioception and protective sensation, characterized by the Semmes-Weinstein monofilament test, and visual and analog pain scoring will also be evaluated before and after each Photon Therapy treatment. 4. Finding: To date, we have just completed 120 patients, using a block randomization scheme not previously reported in this field. We have collected data on nerve function, pain, quality of life, and skin circulation. The data will remain stored until the study is complete to preserve the blinded nature of the project. Data analysis is still incomplete. 4. Clinical Significance Diabetic neuropathy is a chronic and progressive condition that potentially leads to disabling pain, and worse, amputation, for many individuals in the United States each year. Present treatments utilize antiseizure medications, opiate analgesics, and antidepressants, and are inconsistently effective. Development of a new treatment strategy potentially could have significant benefit for a great many patients.
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of 200 mg of RWJ-333369 given twice daily by mouth compared with placebo in the treatment of Diabetic Peripheral Neuropathy (DPN).